Dean Falb – Chief Technology Officer


Dean Falb, CTO of Synlogic, Inc. is responsible for platform technology development and therapeutic program initiation. Previously, Dean was an entrepreneur in residence at Atlas Ventures and worked on several of its emerging portfolio companies. Prior to this he was Vice President of Research and Development at Stryker’s Regenerative Medicine Division. There he led the discovery and development of a portfolio of Bone Morphogenetic Protein (BMP) – based drugs and drug device combinations and launched clinical programs in osteoarthritis. Dean was Sr. Vice President of R&D at Praecis Pharmaceuticals where he led the discovery and development of peptide-based drugs in several therapeutic indications including Plenaxis, which was approved by the FDA for patients with prostate cancer. In 1993 Dean was hired as a founding scientist at Millennium Pharmaceuticals where he started and led Millennium’s program in Cardiovascular Diseases. There he discovered the SMAD signal transduction family which functions downstream of BMP/TGF-beta receptors. He also led a large collaboration with Eli Lilly around the genetics and genomics of cardiovascular diseases. Before Millennium, Dean was a scientist at Immulogic Pharmaceuticals. Dean received his Ph.D. in Biochemistry and Molecular Biology in the lab of Tom Maniatis at Harvard University.